Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Related posts

• INSP NEWS: Inspire Medical Systems, Inc. Sued for Securities Fraud after Stock Plummets 32% — Investors Notified to Contact BFA Law by January 5 Deadline

  December 3, 2025 GlobeNewswire 0

  INSP NEWS: Inspire Medical Systems, Inc. Sued for Securities Fraud after Stock Plummets 32% — Investors Notified to Contact BFA Law by January 5 Deadline

  Source: Medical

  Medical 

• Junction Brain Health Opens Toledo Clinic

  December 1, 2025 GlobeNewswire 0

  Junction Brain Health Opens Toledo Clinic

  Source: Medical

  Medical 

• INSP LEGAL ALERT: Inspire Medical Systems, Inc. Hit with Securities Fraud Class Action due to Product Delays — Investors Notified to Contact BFA Law by January 5

  December 1, 2025 GlobeNewswire 0

  INSP LEGAL ALERT: Inspire Medical Systems, Inc. Hit with Securities Fraud Class Action due to Product Delays — Investors Notified to Contact BFA Law by January 5

  Source: Medical

  Medical